Biogen Inc. (BIIB) on Decifer

Why it ranks here

• Its returns on invested money are modest, around 7% and it turns most of its profit into real cash.
• Revenue is expected to grow about 3% a year, profits are expected to grow 30%, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• It trades about 315% above similar companies, and its growth does not yet back up that price.

The current read

The evidence on BIIB lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Biogen Inc. sits in the biotech layer of the Healthcare, Biotech & Devices story.

Read the full BIIB research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.